Copyright
©The Author(s) 2020.
World J Hepatol. Dec 27, 2020; 12(12): 1326-1340
Published online Dec 27, 2020. doi: 10.4254/wjh.v12.i12.1326
Published online Dec 27, 2020. doi: 10.4254/wjh.v12.i12.1326
Table 1 Characteristics of the patients with no subclinical proximal tubulopathy at on day 0
| Variables | Global (n = 138); n (%) ou; median (Q1; Q3); (n) (min-max) | ETV (n = 28); n (%) ou; median (Q1; Q3) (n) (min-max) | Naive (n = 84); n (%) ou; median (Q1; Q3) (n) (min-max) | TDF (n = 26); n (%) ou; median (Q1; Q3) (n) (min-max) | P value; ETV vs naive | P value; TDF vs naive | |
| Male | 72 (52.2%) | 19 (67.9%) | 39 (46.4%) | 14 (53.8%) | 0.051 | 0.511 | |
| Age in yr | 37.5 (29; 47); (n = 138); (18-74) | 45.5 (31; 57.5); (n = 28); (18-66) | 36.5 (29; 45); (n = 84); (18-74) | 35.5 (24; 42) (n = 26); (21-56) | 0.082 | 0.222 | |
| BMI in kg/m2 | 24.5 (21.3; 27.8); (n = 115); (16.6-38.8) | 25 (22.2; 29); (n = 24); (16.6-36.3) | 24.8 (21.7; 28.7); (n = 71); (17.8-38.8) | 21.8 (19; 26.5); (n = 20); (18-35.2) | 0.912 | 0.022 | |
| Ethnicity | |||||||
| -African | 65 (47.1%) | 7 (25.0%) | 44 (52.4%) | 14 (53.8%) | 0.0033 | 0.053 | |
| -Asian | 16 (11.6%) | 7 (25.0%) | 4 (4.8%) | 5 (19.2%) | |||
| -White | 57 (41.3%) | 14 (50.0%) | 36 (42.9%) | 7 (26.9%) | |||
| Phases of infection | |||||||
| -HbeAg + chronic infection | 6 (4.3%) | 3 (10.7%) | 3 (3.6%) | 0 (0.0%) | < 0.00013 | < 0.00013 | |
| -HbeAg + chronic hepatitis | 15 (10.9%) | 6 (21.4%) | 3 (3.6%) | 6 (23.1%) | |||
| -HbeAg-chronic infection | 60 (43.5%) | 1 (3.6%) | 57 (67.9%) | 2 (7.7%) | |||
| -HbeAg-chronic hepatitis | 57 (41.3%) | 18 (64.3%) | 21 (25.0%) | 18 (69.2%) | |||
| Diabetes | 9 (6.5%) | 5 (17.9%) | 4 (4.8%) | 0 (0.0%) | 0.043 | 0.573 | |
| High blood pressure | 25 (18.1%) | 9 (32.1%) | 12 (14.3%) | 4 (15.4%) | 0.041 | 1.003 | |
| Renal insufficiency | 1 (0.7%) | 0 (0%) | 1 (1.2%) | 0 (0%) | 1.003 | 1.003 | |
| Viral load | |||||||
| -PCR < 2000 UI/mL | 69 (61.6%) | 3 (15.8%) | 60 (77.9%) | 6 (37.5%) | < 0.00013 | < 0.00013 | |
| -PCR ≥ 2000 et < 20000 UI/mL | 22 (19.6%) | 6 (31.6%) | 16 (20.8%) | 0 (0%) | |||
| -PCR ≥ 20000 UI/mL and < 7 (log) | 13 (11.6%) | 6 (31.6%) | 1 (1.3%) | 6 (37.5%) | |||
| PCR > 7 (log) | 8 (7.1%) | 4 (21.1%) | 0 (0%) | 4 (2.5%) | < 0.00012 | < 0.00013 | |
| ALAT UI/L | 25 (17; 36); (n = 133); (7-214) | 40 (25; 57); (n = 27); (17-148) | 19 (15; 26); (n = 83); (7-89) | 46 (28; 70); (n = 23); (10-214) | |||
| Fibrosis4 | |||||||
| -F0/F15 | 103 (84.4%) | 13 (56.5%) | 73 (94.8%) | 17 (77.3%) | < 0.00013 | 0.00673 | |
| -F2 | 5 (4.1%) | 2 (8.7%) | 2 (2.6%) | 1 (4.5%) | |||
| -F2/F3 | 8 (6.6%) | 6 (26.1%) | 2 (2.6%) | 0 (0%) | |||
| -F3 | 1 (0.8%) | 0 (0.0%) | 0 (0%) | 1 (4.5%) | |||
| -F3/F4 | |||||||
| -F4 | 5 (4.1%) | 2 (8.7%) | 0 (0%) | 3 (13.6%) | |||
| Fibrosis F0/F1 vs F2 | |||||||
| -F0/F1 | 103 (84.4%) | 13 (56.5%) | 73 (94.8%) | 17 (77.3%) | < 0.00013 | 0.023 | |
| -≥ F2 | 19 (15.6%) | 10 (43.5%) | 4 (5.2%) | 5 (22.7%) | |||
| Previous HBV therapy | 14 (10.1%) | 5 (17.9%) | 0 (0.0%) | 9 (34.6%) | 0.00073 | < 0.00013 | |
| Nephrotoxic drugs | 12 (6.1%) | 4 (10.5%) | 6 (5.2%) | 2 (4.8%) | 0.223 | 1.003 | |
- Citation: Brayette A, Essig M, Carrier P, Debette-Gratien M, Labrunie A, Alain S, Maynard M, Ganne-Carrié N, Nguyen-Khac E, Pinet P, De Ledinghen V, Renou C, Mathurin P, Vanlemmens C, Di Martino V, Gervais A, Foucher J, Isabelle FH, Vergniol J, Hourmand-Ollivier I, Cohen D, Duval X, Poynard T, Bardou M, Abergel A, Dao MT, Thévenot T, Hiriart JB, Canva V, Lassailly G, Aurières C, Boyer N, Thabut D, Bernard PH, Schnee M, Larrey D, Hanslik B, Hommel S, Jacques J, Loustaud-Ratti V. Subclinical proximal tubulopathy in hepatitis B: The roles of nucleot(s)ide analogue treatment and the hepatitis B virus. World J Hepatol 2020; 12(12): 1326-1340
- URL: https://www.wjgnet.com/1948-5182/full/v12/i12/1326.htm
- DOI: https://dx.doi.org/10.4254/wjh.v12.i12.1326